thalidomide has been researched along with piperidines in 73 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (20.55) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (9.59) | 29.6817 |
| 2010's | 44 (60.27) | 24.3611 |
| 2020's | 7 (9.59) | 2.80 |
| Authors | Studies |
|---|---|
| Koch, H; Pischek, G | 1 |
| Ashkenazi, R; Youdim, MB | 1 |
| Kyogoku, Y; Yu, NT | 1 |
| Koch, H; Stockinger, L | 1 |
| Koch, H; Köhler, F | 1 |
| Jordan, RL; Schumacher, HJ; Terapane, J; Wilson, JG | 1 |
| Champy-Hatem, S | 2 |
| Steiner, R | 1 |
| Coulson, AS; Hellmann, K; Lindahl-Kiessling, K; Summers, LJ; Tucker, D | 1 |
| Brode, E | 1 |
| Blake, MI; Fang, SM; Rhodes, HJ | 1 |
| FRATTA, I; SIGG, EB; WUEST, HM | 1 |
| FABRO, S; SCHUMACHER, H; SMITH, RL; WILLIAMS, RT | 1 |
| KNOCHE, C; KOENIG, J | 1 |
| Brossi, A; Giordano, T; Greig, NH; Holloway, HW; Lahiri, DK; Perry, TA; Yu, QS; Zhu, X | 1 |
| Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N | 1 |
| Byun, JS; De Luca, P; De Siervi, A; Figg, WD; Gardner, K; Ge, Y; Gueron, G; Haggerty, CM; Li, QQ; Quintero, J; Sadiq-Ali, SG; Yabe, IM | 1 |
| Blum, KA; Byrd, JC; Dalton, JT; Farley, KL; Grever, MR; Hofmeister, CC; Johnson, AJ; Liu, Q; Muthusamy, N; Phelps, MA; Schaaf, LJ | 1 |
| Lin, TS | 2 |
| Brown, ST; Greenstein, RJ; Su, L | 1 |
| Horn, L; Sandler, AB | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Brossi, A; Greig, NH; Holloway, HW; Lahiri, DK; Luo, W; Salcedo, I; Tweedie, D; Yu, QS | 1 |
| Ohmachi, K | 1 |
| Balasubramanian, S; Buggy, JJ; Ceribelli, M; Emre, NC; Ferrer, M; Guha, R; Kohlhammer, H; Mathews, LA; Platig, J; Powell, J; Shaffer, AL; Shinn, P; Staudt, LM; Thomas, C; Waldmann, TA; Wright, G; Xiao, W; Xu, W; Yang, Y; Young, RM; Zhang, M; Zhao, H | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L | 1 |
| Crow, JM | 1 |
| Orlowski, RZ | 1 |
| Blum, KA; Maddocks, K | 1 |
| Fraser, K | 1 |
| El-Shentenawy, A; Mohammed, AA | 1 |
| Leonardi, CL; Sobell, JM | 1 |
| Yamamoto, K | 1 |
| Foley, P; Kelly, JB; Strober, BE | 1 |
| Abdul-Hay, M; Desai, AV; El-Bakkar, H | 1 |
| Govindarajulu, B; Rangasamy, M; Thappali, S; Vakkalanka, S; Veeraraghavan, S; Viswanadha, S | 1 |
| Adusumilli, M; Andritsos, LA; Blum, KA; Byrd, JC; Cardone, MH; Doykin, C; Flynn, J; Grever, MR; Jiang, Y; Johnson, AJ; Jones, JA; Maddocks, K; Phelps, MA; Pierceall, WE; Rozewski, D; Wei, L; Zhao, Y | 1 |
| Goldenberg, G; Mansouri, Y | 1 |
| Cotignola, J; De Luca, P; De Siervi, A; Elguero, B; Figg, WD; Gardner, K; Meiss, R; Spallanzani, RG; Vallecorsa, P; Vazquez, E; Zalazar, F | 1 |
| Gong, J; Mita, M; Rimel, B; Sachdev, E | 1 |
| Haq, W; Tiwari, VS; Yadav, SR | 1 |
| Koo, J; Levin, E; McAndrew, R | 1 |
| Robak, T; Smolewski, P; Witkowska, M | 1 |
| Cheah, CY; Seymour, JF; Wang, ML | 1 |
| Warren, RB; Yiu, ZZ | 1 |
| Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S | 1 |
| Chen, L; de Miranda, NF; Dlugosz-Danecka, M; Galazka, K; Jurczak, W; Machaczka, M; Mansouri, L; Morin, RD; Pan-Hammarström, Q; Peng, R; Rosenquist, R; Sander, B; Wasik, AM; Wu, C; Zhang, H | 1 |
| Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Davids, MS; Jung, SH; Leonard, JP; Levine, E; Lewis, LD; Martin, P; Park, SI; Pitcher, B; Smith, SE; Smith, SM; Ujjani, CS | 1 |
| Braun, J | 1 |
| Apollonio, B; Chiu, H; Chopra, R; Couto, S; Flynt, E; Gandhi, AK; Hagner, PR; Ortiz, M; Ramsay, AG; Thakurta, A; Trotter, M; Waldman, MF; Wang, M | 1 |
| Benigno, C; Bertolini, N; Caso, F; Caso, P; Chimenti, MS; Costa, L; Del Puente, A; Girolimetto, N; Peluso, R; Perricone, R; Sabbatino, V; Scarpa, R; Tasso, M | 1 |
| Barnett, E; Bravo, MC; Ghosh, N; Goy, A; Hamadani, M; Lossos, IS; Martin, P; Phillips, T; Reeder, CB; Rule, S; Schuster, SJ; Wang, M | 1 |
| Cardwell, LA; Cline, A; Feldman, SR | 1 |
| Balabanov, S; Cozzio, A; Dummer, R; Fehrenbacher, B; French, LE; Guenova, E; Hoetzenecker, W; Jochum, W; Kamarachev, J; Kerl, K; Metzler, G; Roider, E; Schaller, M; Signer, C | 1 |
| Thieblemont, C | 1 |
| Dahl, C; Eskelund, CW; Geisler, CH; Grønbæk, K; Hutchings, M; Jerkeman, M; Kolstad, A; Kuitunen, H; Laurell, A; Niemann, CU; Pedersen, LB; Räty, R; Toldbod, H; Wader, KF | 1 |
| Lacour, JP | 1 |
| Ding, N; Gao, H; Hwang, J; Liu, W; Rao, Y; Song, Y; Sun, Y; Wu, Y; Yang, Y; Zhao, M; Zhao, X | 1 |
| Armstrong, AW; Singh, S | 1 |
| Elman, SA; Merola, JF; Weinblatt, M | 1 |
| Batchelor, TT; Grommes, C; Nayak, L; Tun, HW | 1 |
| Dressler, C; Eisert, L; Nast, A; Pham, PA; Werner, RN | 1 |
| Lee, YH; Song, GG | 1 |
| Gilhar, A; Keren, A; Laufer Britva, R; Paus, R | 1 |
| Caso, F; Chimenti, MS; Costa, L; Del Puente, A; Giacomelli, R; Girolimetto, N; Navarini, L; Ruscitti, P; Scarpa, R | 1 |
| Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Prater, EF; Rahimi, RS; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Tapper, EB; Wong, EB; Wu, JJ | 1 |
| Chen, L; Li, H; Liu, Y; Wang, Q; Wu, C; Yang, K; Zheng, M; Zhou, Y | 1 |
| Ariani, A; Becciolini, A; Di Donato, E; Giordano, S; Lucchini, G; Lumetti, F; Mozzani, F; Riva, M; Santilli, D | 1 |
| Artamonova, OG; Karamova, AE; Kubanov, AA; Nikonorov, AA; Vasileva, EL; Verbenko, DA | 1 |
| Duvic, M; Joshi, TP | 1 |
30 review(s) available for thalidomide and piperidines
| Article | Year |
|---|---|
[Anti angiogenesis].
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lung Neoplasms; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase Inhibitors; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Piperidines; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Quinazolines; Research Design; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Flavonoids; Humans; Indoles; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Maximum Tolerated Dose; Nitrogen Mustard Compounds; Piperidines; Pyrroles; Thalidomide; Thionucleotides; Treatment Outcome | 2008 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
New agents in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drugs, Investigational; Flavonoids; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Thalidomide | 2010 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
[Present status and perspective of targeted therapy for B-cell lymphoma].
Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Discovery; Flavonoids; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protease Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein-Tyrosine Kinases; Pyrazines; Rituximab; Thalidomide; Vorinostat | 2011 |
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome | 2014 |
Advanced thyroid cancers: new era of treatment.
Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms | 2014 |
Therapeutic development in psoriasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Humans; Immunologic Factors; Interleukin-23; Phosphodiesterase Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide; Treatment Outcome | 2014 |
[Standard of care and new drugs for diffuse large B-cell lymphoma].
Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Discovery; Epigenesis, Genetic; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Molecular Targeted Therapy; Piperidines; Prednisolone; Prednisone; Pyrazoles; Pyrimidines; Radiotherapy, Adjuvant; Rituximab; Thalidomide; Vincristine; Vindesine | 2014 |
Current and future oral systemic therapies for psoriasis.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Cyclosporine; Fumarates; Humans; Hydroxyurea; Immunosuppressive Agents; Isoxazoles; Keratolytic Agents; Leflunomide; Methotrexate; Mycophenolic Acid; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Thioguanine | 2015 |
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Flavonoids; Humans; Immunologic Factors; Indolizines; Isoquinolines; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyridinium Compounds; Pyrimidines; Quinazolinones; Receptors, Antigen, T-Cell; Sulfonamides; Thalidomide | 2015 |
New systemic therapies for psoriasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Factors; Humans; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide | 2015 |
Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Humans; Immunologic Factors; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Thalidomide | 2015 |
Treatment options for mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Piperidines; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Thalidomide | 2015 |
Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cytarabine; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Rituximab; Thalidomide; Transplantation, Autologous | 2016 |
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles | 2016 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia | 2016 |
New targets in psoriatic arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Cyclophosphamide; Etanercept; Humans; Infliximab; Methotrexate; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Ustekinumab | 2016 |
Small molecule therapy for managing moderate to severe psoriatic arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Humans; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Small Molecule Libraries; Thalidomide; Treatment Outcome | 2017 |
Advances in treating psoriasis in the elderly with small molecule inhibitors.
Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide | 2017 |
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Splenic Neoplasms; Survival Rate; Thalidomide | 2017 |
Oral small molecules for psoriasis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Humans; Patient Selection; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide; Thiazoles | 2018 |
Targeted therapies for psoriatic arthritis: an update for the dermatologist.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Psoriatic; Dermatologic Agents; Dermatology; Humans; Interleukin-17; Interleukin-23; Janus Kinase Inhibitors; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Thalidomide; Tumor Necrosis Factor-alpha | 2018 |
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape | 2019 |
Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Confidence Intervals; Humans; Infliximab; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Thalidomide; Time Factors; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Ustekinumab | 2019 |
Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Bayes Theorem; Humans; Network Meta-Analysis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2019 |
Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Psoriatic; Azetidines; Humans; Janus Kinases; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Thalidomide; Treatment Outcome | 2020 |
Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options.
Topics: Anti-Infective Agents; Antimalarials; Biological Therapy; Comorbidity; Dermatologic Agents; Diabetes Complications; Diagnosis, Differential; Glucocorticoids; Granuloma Annulare; Humans; Iatrogenic Disease; Infections; Methotrexate; Neoplasms; Pentoxifylline; Phosphodiesterase 4 Inhibitors; Phototherapy; Piperidines; Pyrimidines; Thalidomide | 2022 |
6 trial(s) available for thalidomide and piperidines
| Article | Year |
|---|---|
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
Topics: Chromatography, Liquid; Flavonoids; Humans; Lenalidomide; Multiple Myeloma; Piperidines; Recurrence; Spectrometry, Mass, Electrospray Ionization; Thalidomide; Time Factors | 2008 |
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Recurrence; Thalidomide; Treatment Outcome; Tumor Lysis Syndrome | 2015 |
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Thalidomide | 2016 |
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Topics: Adaptor Proteins, Signal Transducing; Adenine; Coculture Techniques; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphocyte Count; Lymphoma, Mantle-Cell; Mutation; Peptide Hydrolases; Piperidines; Pyrazoles; Pyrimidines; Thalidomide; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2017 |
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Rituximab; Survival Analysis; Thalidomide; Treatment Outcome | 2018 |
The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
Topics: Adult; Cohort Studies; Cytokines; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Pyrimidines; Severity of Illness Index; Skin; Thalidomide; Treatment Outcome; Young Adult | 2021 |
37 other study(ies) available for thalidomide and piperidines
| Article | Year |
|---|---|
[The biologic half-life of the thalidomide-like compound K-2004 (author's transl)].
Topics: Animals; Bridged Bicyclo Compounds; Bridged-Ring Compounds; Half-Life; Hypnotics and Sedatives; Intestinal Absorption; Male; Piperidines; Piperidones; Rats; Thalidomide | 1975 |
Serotonergic involvement in pharmacological action of the anxiolytic-sedatives thalidomide and supidimide.
Topics: Animals; Anti-Anxiety Agents; Brain; Catecholamines; Clorgyline; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Male; Methoxydimethyltryptamines; Monoamine Oxidase; Motor Activity; p-Chloroamphetamine; Piperidines; Platelet Aggregation; Rats; Rats, Inbred Strains; Serotonin; Serotonin Antagonists; Thalidomide; Tranylcypromine; Tryptophan | 1985 |
Specific H-bonding of glutarimides and hydantoins to derivatives of RNA bases in chloroform solution.
Topics: Bemegride; Chemical Phenomena; Chemistry; Chloroform; Cycloheximide; Ethosuximide; Glutethimide; Hydantoins; Pemoline; Phenobarbital; Phenytoin; Piperidines; Piperidones; Primidone; RNA; Spectrophotometry, Infrared; Thalidomide | 1973 |
[Teratologic study of a new, structurally related to thalidomide, sedative-hypnotic effective compound (K-2004)].
Topics: Abdominal Muscles; Abnormalities, Drug-Induced; Animals; Embryo, Mammalian; Female; Fetal Death; Hernia; Hypnotics and Sedatives; Limb Deformities, Congenital; Meningocele; Piperidines; Pregnancy; Rabbits; Tail; Thalidomide | 1969 |
[Teratological study on the thalidomide-like compounds K-2004 and K-2604 in the mouse and rat].
Topics: Abnormalities, Drug-Induced; Animals; Bridged Bicyclo Compounds; Bridged-Ring Compounds; Drug Evaluation, Preclinical; Female; Fetus; Hypnotics and Sedatives; Imides; Injections, Intraperitoneal; Mice; Piperidines; Piperidones; Pregnancy; Rats; Teratogens; Thalidomide | 1974 |
The teratogenic activity of a thalidomide analogue, EM 12 in rabbits, rats, and monkeys.
Topics: Abnormalities, Drug-Induced; Animals; Bone and Bones; Bone Diseases, Developmental; Female; Fetal Death; Fetal Diseases; Forelimb; Gestational Age; Haplorhini; Hindlimb; Injections, Intravenous; Macaca; Piperidines; Pregnancy; Pyrrolidinones; Rabbits; Rats; Species Specificity; Spine; Thalidomide; Time Factors; Wrist | 1972 |
[Glutarimide and the action of thalidomide. Spectral study extended to approximately 2,050 A].
Topics: Piperidines; Spectrum Analysis; Thalidomide | 1965 |
Non-barbiturate hypnotics.
Topics: Alcohols; Bromides; Chloral Hydrate; Dentistry; Glutethimide; Hypnotics and Sedatives; Paraldehyde; Piperidines; Thalidomide | 1968 |
The effect of two soluble thalidomide derivatives on lymphocyte stimulation.
Topics: Culture Techniques; Depression, Chemical; Formaldehyde; Humans; Isoantigens; Lectins; Lymphocyte Activation; Lymphocytes; Morpholines; Piperidines; Stereoisomerism; Thalidomide; Thymidine | 1970 |
[Conjugated action of the 2 thalidomide nuclei on imidazole compounds: histamine and purine bases].
Topics: Carcinogens; Chemical Phenomena; Chemistry; Histamine; Imidazoles; Imides; Phthalic Acids; Piperidines; Purines; Thalidomide | 1967 |
[Experimental studies with cyclic imides. II. Modification of some somatotropin-dependent processes by cyclic imides].
Topics: Animals; Cartilage; Depression, Chemical; Female; Imides; Male; Piperidines; Pituitary Gland; Rats; Stimulation, Chemical; Sulfates; Sulfur Isotopes; Thalidomide; Tibia | 1968 |
Synthesis of 2,6-dioxo-3-phthalimidopiperidine-3,4,4,5,5-d, and 2,5-dioxo-3-phthalimidopyrrolidine-3,4,4-d, from L-deuterio-glutamic acid and L-deuterio-aspartic acid.
Topics: Aspartic Acid; Carbon; Chemistry, Pharmaceutical; Deuterium; Eukaryota; Glutamates; Hydrogen; Nitrogen; Piperidines; Thalidomide | 1965 |
PHARMACOLOGICAL PROPERTIES AND TERATOGENIC ACTION OF 2-(HEXAHYDROPHTHALIMIDO) GLUTARIMIDE AND 2-PHTHALIMIDO-N-METHYLGLUTARIMIDE.
Topics: Abnormalities, Drug-Induced; Animals; Female; Humans; Mice; Piperidines; Piperidones; Pregnancy; Pregnancy, Animal; Rabbits; Research; Thalidomide; Toxicology | 1964 |
TERATOGENIC ACTIVITY OF THALIDOMIDE AND RELATED COMPOUNDS.
Topics: Abnormalities, Drug-Induced; Animals; Female; Humans; Pharmacology; Piperidines; Pregnancy; Rabbits; Research; Thalidomide; Toxicology | 1964 |
[ON THE PRENATAL TOXICITY OF DIPHENYLPYRALINE 8-CHLOROTHEOPHYLLINATE WITH REFERENCE TO EXPERIENCES WITH THALIDOMIDE AND CAFFEINE].
Topics: Abnormalities, Drug-Induced; Anti-Allergic Agents; Caffeine; Fetal Death; Histamine H1 Antagonists; Mice; Piperidines; Pregnancy; Pregnancy, Animal; Research; Thalidomide; Theophylline; Toxicology | 1964 |
Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity.
Topics: 3' Untranslated Regions; Animals; Cell Line; Genes, Reporter; Humans; In Vitro Techniques; Lipopolysaccharides; Luciferases; Mice; Monocytes; Piperidines; RNA, Messenger; Structure-Activity Relationship; Thalidomide; Thiones; Tumor Necrosis Factor-alpha | 2003 |
Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Death; Cell Line, Tumor; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flavonoids; Free Radical Scavengers; Glutathione; Homeostasis; Humans; Intracellular Space; Leukemia; Membrane Potential, Mitochondrial; Mitochondria; NF-kappa B; Nuclear Proteins; Organ Specificity; Oxidation-Reduction; Piperidines; Proto-Oncogene Proteins; Reactive Oxygen Species; Thalidomide; Transcription, Genetic; Tumor Suppressor Proteins | 2008 |
On the effect of thalidomide on Mycobacterium avium subspecies paratuberculosis in culture.
Topics: Animals; Bacteriological Techniques; Cattle; Culture Media; Humans; Immunosuppressive Agents; Mycobacterium avium subsp. paratuberculosis; Phthalimides; Piperidines; Thalidomide | 2009 |
Design, synthesis and biological assessment of novel N-substituted 3-(phthalimidin-2-yl)-2,6-dioxopiperidines and 3-substituted 2,6-dioxopiperidines for TNF-α inhibitory activity.
Topics: Animals; Cell Line, Tumor; Drug Design; Lenalidomide; Mice; Phthalimides; Piperidines; Thalidomide; Tumor Necrosis Factor-alpha | 2011 |
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Interferon Regulatory Factors; Interferon-beta; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Peptide Hydrolases; Piperidines; Pyrazoles; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thalidomide; Transcription Factors; Tumor Burden; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2012 |
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2013 |
Therapeutics: Silencing psoriasis.
Topics: Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Dermatologic Agents; Humans; Interleukin-17; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Recombinant Fusion Proteins; Thalidomide; Ustekinumab | 2012 |
72nd annual meeting of the American Academy of Dermatology.
Topics: Antifungal Agents; Attention Deficit Disorder with Hyperactivity; Boron Compounds; Botulinum Toxins, Type A; Bridged Bicyclo Compounds, Heterocyclic; Brimonidine Tartrate; Depression; Dermatitis, Atopic; Food Hypersensitivity; Humans; Immunologic Factors; Ivermectin; Phosphodiesterase Inhibitors; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinoxalines; Skin Diseases; Societies, Medical; Thalidomide; Triazoles; United States | 2014 |
Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study.
Topics: Adenine; Animals; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Lenalidomide; Liquid-Liquid Extraction; Male; Piperidines; Plasma; Pyrazoles; Pyrimidines; Rats; Rats, Wistar; Reproducibility of Results; Tandem Mass Spectrometry; Thalidomide; Tolbutamide | 2015 |
Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Combinations; Flavonoids; Humans; Male; Mice; Mice, Nude; Piperidines; Prostatic Neoplasms; Thalidomide; Treatment Outcome | 2015 |
Adnectin-targeted inhibitors: rationale and results.
Topics: Adenine; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fibronectins; Humans; Lenalidomide; Molecular Targeted Therapy; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Pyrazoles; Pyrimidines; Thalidomide; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Stereoselective Synthesis of (R)-3-Methylthalidomide by Piperidin-2-one Ring Assembly Approach.
Topics: Chemistry Techniques, Synthetic; Hydrogen-Ion Concentration; Piperidines; Piperidones; Stereoisomerism; Thalidomide | 2015 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
Topics: Adenine; CARD Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Genetic Heterogeneity; Guanylate Cyclase; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Mutation; NF-kappa B; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Signal Transduction; Thalidomide; Transfection | 2016 |
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Topics: Adenine; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Thalidomide | 2017 |
Individualized treatment approaches for Langerhans cell histiocytosis.
Topics: Adrenal Cortex Hormones; Adult; Aged, 80 and over; Azetidines; Bone Diseases; Dermatologic Agents; Female; Histiocytosis, Langerhans-Cell; Humans; Male; Middle Aged; Off-Label Use; Piperidines; Skin Diseases; Thalidomide | 2018 |
[Current and upcoming treatments of adult atopic dermatitis].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Glucocorticoids; Humans; Methotrexate; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Thalidomide; Ustekinumab | 2017 |
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; HEK293 Cells; HeLa Cells; Humans; Lymphoma, B-Cell; Mutation; Piperidines; Protein Domains; Proteolysis; Pyrazoles; Pyrimidines; Thalidomide | 2018 |
Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata.
Topics: Alopecia Areata; Animals; Mice; Piperidines; Pyrimidines; Pyrroles; Thalidomide | 2020 |
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
Topics: Acitretin; Cyclosporine; Drug Monitoring; Humans; Methotrexate; Piperidines; Psoriasis; Pyrimidines; Thalidomide | 2020 |
Novel PROTACs for degradation of SHP2 protein.
Topics: Cell Cycle; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Molecular Structure; Piperidines; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyrimidines; Structure-Activity Relationship; Thalidomide | 2021 |
Cycling or swap biologics and small molecules in psoriatic arthritis: Observations from a real-life single center cohort.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Biological Products; Cluster Analysis; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrimidines; Thalidomide; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2021 |